Literature DB >> 20334807

[Cystatin C and cardiovascular risk in the general population].

Javier Cepeda1, Salvador Tranche-Iparraguirre, Rafael Marín-Iranzo, Eloy Fernández-Rodríguez, Alba Riesgo-García, Juan García-Casas, Eduardo Hevia-Rodríguez.   

Abstract

INTRODUCTION AND
OBJECTIVES: Cystatin C has been proposed as a novel marker of renal function and as a predictor of cardiovascular risk in the elderly. The aim of this study was to determine the prevalence of an elevated cystatin C level in the general population and its relationship with cardiovascular risk factors and disease.
METHODS: This descriptive epidemiologic cross-sectional study involved a simple randomized sample of individuals aged >49 years from the general population, and was based on personal health records. From the final selection of 415 individuals, 359 underwent cystatin C measurement using a immunonephelometric assay. The cut-point used was that recommended for the method in adults.
RESULTS: Of the 359 individuals (mean+/-standard deviation age, 64+/-10 years, 63.5% female) studied, 17.3% (95% confidence interval [CI] 13.4%-21.2%) had an elevated cystatin C level. The mean level was 0.81+/-0.21 mg/L, and increased with age. Elevation of the cystatin C level was associated with: older age (P< .0001); high measures of systolic blood pressure (P< .0001), hemoglobin A1c (P=.031), triglycerides (P=.019), homocysteine (P< .0001), C-reactive protein (P=.015), fibrinogen (P=.006) and microalbuminuria (P=.001); and a low high-density lipoprotein cholesterol level (P=.021) and estimated glomerular filtration rate (P< .0001). Associated cardiovascular diseases included coronary heart disease (P=.013) and heart failure (P=.038). The main factors independently associated with an elevated cystatin C level were diabetes (odds ratio [OR]=5.37), male sex (OR=4.91) and decreased glomerular filtration (OR=0.83).
CONCLUSIONS: The prevalence of an elevated cystatin C level in the general population was found to be high and was associated with the presence of classical cardiovascular risk factors such as diabetes, hypertension and chronic renal disease, along with higher levels of C-reactive protein, homocysteine and fibrinogen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334807

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  6 in total

1.  Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults.

Authors:  Alex K Bryant; Pariya L Fazeli; Scott L Letendre; Ronald J Ellis; Michael Potter; Tricia H Burdo; Kumud K Singh; Dilip V Jeste; Igor Grant; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-15       Impact factor: 2.205

2.  Arterial indices and serum cystatin C level in individuals with occupational wide band noise exposure.

Authors:  Ali R Khoshdel; Benyamin Mousavi-Asl; Babak Shekarchi; Kazem Amini; Iraj Mirzaii-Dizgah
Journal:  Noise Health       Date:  2016 Nov-Dec       Impact factor: 0.867

Review 3.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

4.  Reference intervals for serum cystatin C and factors influencing cystatin C levels other than renal function in the elderly.

Authors:  Lu Wei; Xiaoshuang Ye; Xiaohua Pei; Jianqing Wu; Weihong Zhao
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

5.  Independent associations of urinary albumin-to-creatinine ratio and serum cystatin C with carotid intima-media thickness in community-living Taiwanese adults.

Authors:  Chiu-Shong Liu; Chia-Ing Li; Yuh-Cherng Guo; Chih-Hsueh Lin; Wen-Yuan Lin; Chung-Hsiang Liu; Mu-Cyun Wang; Chuan-Wei Yang; Shing-Yu Yang; Tsai-Chung Li; Cheng-Chieh Lin
Journal:  BMC Nephrol       Date:  2020-10-31       Impact factor: 2.388

Review 6.  Diabetic patients with chronic kidney disease: Non-invasive assessment of cardiovascular risk.

Authors:  Nejc Piko; Sebastjan Bevc; Robert Ekart; Tadej Petreski; Nina Vodošek Hojs; Radovan Hojs
Journal:  World J Diabetes       Date:  2021-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.